All In Biotech

Drug Trial Radar · NCT06181370

Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of Inhaled AGMB-447 in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 143 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

143

Actual

Start

Dec 1, 2023

Primary completion

Apr 29, 2026

Study completion Apr 29, 2026

Sponsor

Lead sponsor
Agomab Spain S.L.Industry
Sponsor type
Industry
First posted
Dec 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the safety, tolerability PK and PD of inhaled AGMB-477 compared with placebo in healthy participants and participants with IPF. This is an integrated phase 1, single center, 3-part, double-blind, randomized, placebo-controlled SAD (Part A) and MAD (Part B) study in healthy participants and multiple dose study in IPF participants (Part C). Safety, tolerability PK and PD will be assessed following single ascending, multiple ascending and multiple dosing of AGMB-447 administered via nebulizer in Part A, B and C, respectively.

Conditions

  • IPF

Interventions

  • AGMB-447Drug

    AGMB-447 inhaled drug

  • placeboOther

    placebo inhaled drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: From Screening Through Study Completion, up to 8 Weeks
  2. Number of participants with abnormal clinical laboratory valuesTime frame: From Screening Through Study Completion, up to 8 Weeks
  3. Number of participants with abnormal ECG parametersTime frame: From Screening Through Study Completion, up to 8 Weeks
  4. Number of participants with abnormal vital signsTime frame: From Screening Through Study Completion, up to 8 Weeks
  5. Number of participants with abnormal physical examsTime frame: From Screening Through Study Completion, up to 8 Weeks
  6. Number of participants with abnormal spirometry parametersTime frame: From Screening Through Study Completion, up to 8 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medicines Evaluation Unit Ltd. an IQVIA business

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.